FDA approves Omeros’ Yartemlea — first TA‑TMA therapy

The U.S. Food and Drug Administration approved Omeros Corporation’s Yartemlea (narsoplimab) as the first therapy for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA). The approval addresses a life‑threatening complication of hematopoietic stem cell transplantation with no prior approved therapies, setting a regulatory precedent for a rare but severe post‑transplant disorder. Company statements and the FDA notice provide safety and indication details.